Related Experiment Video
Updated: Aug 16, 2026
In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology
Published on: September 29, 2023
In vivo activity of mutacin B-Ny266
Marilaine Mota-Meira1, Helene Morency, Marc C Lavoie
1Department of Biological and Chemical Sciences, Faculty of Pure and Applied Sciences, The University of the West Indies, Cave Hill Campus, PO Box 64, Bridgetown, Barbados.
Objectives:
The objective of this study was to assess the in vivo activity of mutacin B-Ny266 (a bacteriocin produced by Streptococcus mutans) in order to eventually use it as an antibiotic.
Methods:
Intraperitoneal infection was induced with a methicillin-susceptible Staphylococcus aureus strain in mice. Some of the mice were simultaneously injected intraperitoneally with mutacin B-Ny266, some with the vehicle only and some with vancomycin.
Results:
While there was 70 and 100% mortality in the control groups of mice, no mortality was observed in the mice injected with vancomycin or mutacin B-Ny266.
Conclusions:
The results presented here show, for the first time, the in vivo efficacy of a mutacin (B-Ny266) against an experimental intraperitoneal infection by S. aureus in a mouse model.
Insights
Mutacin B-Ny266, a bacteriocin from Streptococcus mutans, demonstrated significant in vivo efficacy. This study shows no mortality in mice infected with Staphylococcus aureus when treated with mutacin B-Ny266 or vancomycin.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Bacteriocins are antimicrobial peptides with potential therapeutic applications.
- Streptococcus mutans produces mutacin B-Ny266, a bacteriocin of interest.
- Antibiotic resistance necessitates the development of novel antimicrobial agents.
Purpose of the Study:
- To evaluate the in vivo antibacterial activity of mutacin B-Ny266.
- To determine the potential of mutacin B-Ny266 as a therapeutic antibiotic against Staphylococcus aureus infections.
Main Methods:
- A mouse model was used to assess intraperitoneal infection with methicillin-susceptible Staphylococcus aureus.
- Mice were treated with mutacin B-Ny266, vancomycin, or vehicle control via intraperitoneal injection.
Main Results:
- Control groups exhibited high mortality rates (70% and 100%).
- No mortality was observed in mice treated with vancomycin.
- Mice treated with mutacin B-Ny266 also showed no mortality, indicating its efficacy.
Conclusions:
- Mutacin B-Ny266 demonstrates in vivo efficacy against experimental Staphylococcus aureus infection in mice.
- This study provides the first evidence of mutacin B-Ny266's effectiveness in a living organism.
- Mutacin B-Ny266 shows promise as a potential antibiotic candidate.
Related Concept Videos
01:25Mutagenicity and Carcinogenicity
01:20Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...